Navigation Links
Amgen Positioned to Deliver Attractive Growth Over Next Five Years
Date:11/7/2008

Application (BLA) data package for denosumab for post menopausal osteoporosis by the end of 2008 or early 2009. Amgen looks forward to working in due course with regulatory authorities and governments worldwide to secure appropriate approval for marketing, coverage and reimbursement for denosumab and other late phase pipeline opportunities.

George Morrow, Amgen's executive vice president for Global Commercial Operations, outlined the critical factors for successfully commercializing denosumab and gave an updated outlook on the Company's marketed products.

"Although we expect an additional decline of 10 to 20 percent in U.S. Aranesp(R) (darbepoetin alfa) sales before relative stability is achieved in the first half of 2009, we also expect sales growth from our overall existing product portfolio to continue," Morrow said. "We are also actively engaged in preparations to deliver on the promise of denosumab."

Robert A. Bradway, Amgen's executive vice president and CFO, shared his perspective on the Company's financial objectives. "After delivering on our restructuring program, we remain focused on optimizing both our cost and capital structures," Bradway said. He noted the Company aspires to be among the top three biopharmaceutical companies in growth over the next five years.

Financial guidance previously provided on Oct. 22, 2008 for 2008 revenue and adjusted earnings per share remains unchanged.

About Amgen

Amgen discovers, develops, manufactures and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, and other serious illnesses. With a deep and broad pipeline of potential new
'/>"/>

SOURCE Amgen
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Amgen and Genentech Brace Themselves for Heavy Pressure From Biogenerics Manufacturers
2. More Than 230 Cyclists to Ride in Amgen California Coast Classic Bike Tour to Raise $1.3 Million for Arthritis Foundation
3. Entry of Biogenerics and Decreasing Use of Amgens Epogen and Johnson & Johnsons Procrit Will Cause a $2.8 Billion Decline in the Drug Market for Chemotherapy-Induced Anemia by 2016
4. Oxford Genome Sciences and Amgen to Jointly Discover Novel Therapeutic Antibodies in Cancer
5. Pfizer, Genentech, Amgen, Bayer, Wyeth, Abbott, Merck and Additional Leading Pharmaceutical Companies Participating During ExL Pharmas Fall Line Up!
6. Co-Inventor of Amgens Aranesp(R) Technology Directs Worldwide Patent Strategy for Diffusion Pharmaceuticals First-in-Class Oxygen Enhancing Therapeutics
7. Amgen Announces Webcast of 2008 Third Quarter Financial Results
8. Amgens Third Quarter 2008 Adjusted Earnings Per Share Increased 14 Percent to $1.23
9. Call for Applications: The Amgen Award for Science Teaching Excellence
10. Amgen to Webcast 2008 Business Review Meeting on November 7 From Millennium Hotel in New York
11. New Therapy by Merck is Positioned to Earn Gold-Standard Status by 2011 in the Treatment of Chemotherapy-Induced Nausea and Vomiting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... work by a Florida State University research team has ... your temperature, emit white light, and convert photon energy ... like a butterfly. , Biwu Ma, associate professor in ... FAMU-FSU College of Engineering, created the molecule in a ... discover that his creation has many other unique capabilities. ...
(Date:8/28/2014)... Earlier this month, a report was ... the U.S. Air Force on the performance of vehicles ... this type of fuel made from mustard seeds, offered ... to America’s Eco friendly future. In fact, every branch ... become independent of foreign oil over the next few ...
(Date:8/28/2014)... 2014 Whitehouse Laboratories is excited to ... with PTI Inspection Systems that will enable ... the art leak testing method development and validation programs ... available. As part of this agreement, Whitehouse Labs has ... Detection Instrument developed and manufactured by PTI. The ...
(Date:8/27/2014)... -- Rhythm, a biopharmaceutical company developing peptide therapeutics that ... metabolic disorders, announced today that it has filed a ... and Exchange Commission (SEC) relating to the proposed initial ... number of shares to be offered and the price ... Citigroup and Cowen and Company will act ...
Breaking Biology Technology:Novel 'butterfly' molecule could build new sensors, photoenergy conversion devices 2Can Small Farmers and a New Seed Based Biofuel “Green” the World? Major Universities and Even the U.S. Air Force Seem to Think So 2Can Small Farmers and a New Seed Based Biofuel “Green” the World? Major Universities and Even the U.S. Air Force Seem to Think So 3Can Small Farmers and a New Seed Based Biofuel “Green” the World? Major Universities and Even the U.S. Air Force Seem to Think So 4Can Small Farmers and a New Seed Based Biofuel “Green” the World? Major Universities and Even the U.S. Air Force Seem to Think So 5Whitehouse Labs Renews Partnership with PTI Inspection Systems 2Whitehouse Labs Renews Partnership with PTI Inspection Systems 3Rhythm Files Registration Statement for Proposed Initial Public Offering 2
... Hosts Three Customer Audits, Continues Growth Strategy ... Industry-Leading Software Tools, MOUNTAIN VIEW, Calif., Dec. ... leading provider of software, strategic,consulting, and regulatory services ... global biopharmaceutical companies,have performed audits of its Reporting ...
... ... - Lead compound AEG40826 works synergistically with HGS TRAIL receptor ... -, - IAP inhibitors also show promise alone and in combination ... agents across broad range of cancers -, ROCKVILLE, Md. and MONTREAL, Quebec, ...
... 20 Human Genome,Sciences, Inc. (Nasdaq: HGSI ... patients in a Phase 2 clinical trial of ... and carboplatin as,first-line therapy in patients with advanced ... patients who are newly diagnosed with non-small cell,lung ...
Cached Biology Technology:Pharsight's Reporting and Analysis Services Business Reaches Quality Assurance Milestone 2Pharsight's Reporting and Analysis Services Business Reaches Quality Assurance Milestone 3Pharsight's Reporting and Analysis Services Business Reaches Quality Assurance Milestone 4Human Genome Sciences and Aegera Therapeutics Announce Licensing and Collaboration Agreement on Novel Anti-Cancer Drugs 2Human Genome Sciences and Aegera Therapeutics Announce Licensing and Collaboration Agreement on Novel Anti-Cancer Drugs 3Human Genome Sciences and Aegera Therapeutics Announce Licensing and Collaboration Agreement on Novel Anti-Cancer Drugs 4Human Genome Sciences and Aegera Therapeutics Announce Licensing and Collaboration Agreement on Novel Anti-Cancer Drugs 5Human Genome Sciences and Aegera Therapeutics Announce Licensing and Collaboration Agreement on Novel Anti-Cancer Drugs 6Human Genome Sciences Initiates Second Randomized Phase 2 Trial of HGS-ETR1 in Combination With Chemotherapy 2Human Genome Sciences Initiates Second Randomized Phase 2 Trial of HGS-ETR1 in Combination With Chemotherapy 3Human Genome Sciences Initiates Second Randomized Phase 2 Trial of HGS-ETR1 in Combination With Chemotherapy 4Human Genome Sciences Initiates Second Randomized Phase 2 Trial of HGS-ETR1 in Combination With Chemotherapy 5Human Genome Sciences Initiates Second Randomized Phase 2 Trial of HGS-ETR1 in Combination With Chemotherapy 6
(Date:8/27/2014)... Using functional near infrared spectroscopy (fNIRS), Kessler Foundation ... people with multiple sclerosis (MS) and healthy controls. ... brain activation was studied using fNIRS while participants ... cognition using functional near infrared spectroscopy (fNIRS) in ... by Brain Imaging and Behavior . Authors ...
(Date:8/27/2014)... 400 million years ago a group of fish began exploring ... and mammals. But just how these ancient fish used their ... evolutionary processes were at play remain scientific mysteries. , ... , turned to a living fish, called Polypterus , ... attempted to walk out of the water. Polypterus ...
(Date:8/27/2014)... is easier when it is related to ability that ... learn a new melody more easily than learning how ... the Center for the Neural Basis of Cognition (CNBC)a ... Mellon Universityhave discovered a fundamental constraint in the brain ... cover story in the Aug. 28, 2014, issue of ...
Breaking Biology News(10 mins):Kessler Foundation researchers publish first study of brain activation in MS using fNIRS 2Walking fish reveal how our ancestors evolved onto land 2Pitt and Carnegie Mellon engineers discover why learning can be difficult 2Pitt and Carnegie Mellon engineers discover why learning can be difficult 3
... PARK, MD, April 7, 2009 -- Roughly 20 percent ... homes, businesses, and other private and public spaces. Though ... also presents a tremendous opportunity for savings. Improving the ... little -- could translate into dramatically lower energy usage ...
... microbes that live within the plumbing of deep-sea mud ... resemble those in extraterrestrial environments and early Earth. The ... Foundation (NSF), was conducted in an area where clusters ... that support food chains independently of the Sun. ...
... researcher, Dr. Mark Flynn,s high-speed flywheel motor controller is ... the world. Flynn,s design has been incorporated into energy ... and sold by VYCON Inc. The 8,000 RTG ... significantly to port emissions and, as such, have ...
Cached Biology News:Cheap and efficient white light LEDs new design described in AIP's Journal of Applied Physics 2Cheap and efficient white light LEDs new design described in AIP's Journal of Applied Physics 3Better living through chemistry 2Better living through chemistry 3Saving energy and the environment with Flywheels 2
Mouse monoclonal [AE3] to Cytokeratin 1 - 8, prediluted ( Abpromise for all tested applications). Antigen: Tissue / cell preparation - Human epidermal cells. Entrez GeneID: 140807 Swiss P...
pETDuet-1 is designed for the coexpression of two target genes....
...
WIF-1 (N-20)...
Biology Products: